Techniques for analyzing circulating tumor DNA (ctDNA) to detect, characterize and monitor
cancer have matured rapidly. An increasing body of clinical evidence is demonstrating the …

Colorectal cancer (CRC) is one of the most prevalent and deadly cancers worldwide.
Despite recent improvements in treatment and prevention, most of the current therapeutic …

The emerging field of liquid biopsy stands at the forefront of novel diagnostic strategies for
cancer and other diseases. Liquid biopsy allows minimally invasive molecular …

Sequential profiling of plasma cell-free DNA (cfDNA) holds immense promise for early
detection of patient progression. However, how to exploit the predictive power of cfDNA as a …

High inter-patient variability and high spatial heterogeneity are features of colorectal cancer
(CRC). This may influence the molecular characterization of tumor tissue, now mandatory for …

Highlights•The epidermal growth factor (EGFR) is a therapeutic option for patients with all
RAS WT metastatic colorectal cancer (mCRC).•A better knowledge of the mechanism of …

PURPOSE Low concordance between plasma-based and tissue-based tests for determining
the RAS mutational status have been reported in some but not all patients with limited-extent …

Certain genetic alterations and right-sided primary tumor location are associated with
resistance to anti-epidermal growth factor (EGFR) treatment in metastatic colorectal cancer …

Background RAS mutations are currently sought for in tumor samples, which takes a median
of almost 3 weeks in western European countries. This creates problems in clinical …

The term liquid biopsy refers to the analysis of biomarkers in any body fluid, including blood,
urine and cerebrospinal fluid. In cancer, liquid biopsy testing allows the analysis of tumor …